Projects per year
Personal profile
Research interests
Research Expertise:
Organic & Medicinal Chemistry | Organoboron Chemistry | Alternate Energy Materials
Medicinal Chemistry: We have been developing novel aza- and bora-heterocyclic compounds and betulin-based natural product derivatives as anti-cancer agents. In collaboration with Rowan School of Osteopathic Medicine, we have also identified few Withaferin-serotonin conjugates as potential therapeutic options for the treatment of Alzheimers’ Disease.
Value Added Chemicals from Biomass: Recent efforts in this area have included the development of new protocols for the effective conversion of biomass derived cellulosic materials into chemicals such as hydroxymethyl furfural and furan dicarboxylic acid for applications as bio-based polymers.
Honors and Awards:
Rowan University Wall of Fame Teaching Award, 2013, 2016
Eli Lilly International Graduate Scholar, 2000-2005, Purdue University
Member of:
American Chemical Society (www.acs.org)
Education/Academic qualification
Doctor of Philosophy, doctorate
Bachelor of Science, Bachelor, Pondicherry University
Master of Science, Master, University of Hyderabad
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
HNK analog as an approach to non-opioid analgesics
Jonnalagadda, S. (PI)
10/1/25 → 9/30/27
Project: Other project
-
Discovering Chemical Activity Networks-Predicting Bioactivity Based on Structure
Jonnalagadda, S. (PI)
2/1/23 → 1/31/29
Project: Other project
-
Mechanism-Driven Virtual Adverse Outcome Pathway Modeling for Hepatotoxicity
Jonnalagadda, S. (PI)
9/1/24 → 1/31/26
Project: Other project
-
Development of Novel Therapeutic Agents for the Treatment of Triple Negative Breast Cancer
Jonnalagadda, S. (PI)
New Jersey Health Foundation, Inc. (NJHF)
2/15/24 → 2/13/26
Project: Other project
-
Collaborative Research: III: Medium: New Machine Learning Empowered Nanoinformatics System for Advancing Nanomaterial Design
Jonnalagadda, S. (PI)
2/1/24 → 1/31/25
Project: Other project
-
Saga of MCL1 inhibitors in multiple myeloma
Nelson, E., Telang, S. P., Budak-Alpdogan, T., Jonnalagadda, S. C., Srivastava, S. K. & Pandey, M. K., Jan 2026, In: Biochemical Pharmacology. 243, 117532.Research output: Contribution to journal › Review article › peer-review
Open Access -
Unlocking nature's potential: Soursop in the battle against resistant acute myeloid leukemia
Paparo, S. M., Mendoza, R. M., Jethi, S., Brister, M., Jonnalagadda, S. C., Budak-Alpdogan, T., Strair, R. & Pandey, M. K., Dec 2025, In: Biochemistry and Biophysics Reports. 44, 102354.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients
Al-Odat, O. S., Nelson, E., Budak-Alpdogan, T., Jonnalagadda, S. C., Desai, D. & Pandey, M. K., Jul 2024, In: Cancers. 16, 13, 2381.Research output: Contribution to journal › Review article › peer-review
Open Access3 Link opens in a new tab Scopus citations -
KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis
Al-Odat, O. S., Elbezanti, W. O., Gowda, K., Srivastava, S. K., Amin, S. G., Jonnalagadda, S. C., Budak-Alpdogan, T. & Pandey, M. K., 2024, In: Frontiers in Pharmacology. 15, 1436786.Research output: Contribution to journal › Article › peer-review
Open Access4 Link opens in a new tab Scopus citations -
Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells
Bhowmick, K., von Suskil, M., Al-Odat, O. S., Elbezanti, W. O., Jonnalagadda, S. C., Budak-Alpdogan, T. & Pandey, M. K., Jun 30 2024, In: Heliyon. 10, 12, e33091.Research output: Contribution to journal › Review article › peer-review
Open Access15 Link opens in a new tab Scopus citations